7-OH Kratom Clinical Effects Characterized at Virginia Poison Center for First Time

Why it matters

Virginia Commonwealth University researchers published the first systematic characterization of 7-OH's clinical effects using real-world poison center data, providing clinicians with a concrete profile of 7-OH toxicity separate from traditional kratom leaf exposure.

The big picture

As 7-hydroxymitragynine products proliferate—often sold as kratom but containing synthetic or concentrated 7-OH—clinicians lack clear guidance on what to expect in acute exposure scenarios. This descriptive study from VCU's Division of Clinical Toxicology analyzes cases from a single high-volume poison center and addresses a significant gap in toxicological literature. The findings are especially timely given that multiple states and the FDA are actively debating how to regulate 7-OH differently from whole-leaf kratom.

Key findings

• Researchers at VCU Health analyzed 7-OH exposure cases from a regional poison center receiving approximately 30,000 annual human exposure calls
• The study is among the first peer-reviewed clinical characterizations of 7-OH as a distinct toxicological entity separate from mitragynine
• Authors describe opioid-receptor mediated effects consistent with 7-OH's known pharmacological profile, including CNS and respiratory depression
• The paper helps clinicians differentiate 7-OH toxicity from traditional kratom leaf exposure in emergency settings
• Study appeared in American Journal of Therapeutics on April 29, 2026 (DOI: 10.1097/MJT.0000000000002134)

What they say

The authors note that their findings underscore the need for clinicians to distinguish between natural kratom leaf and concentrated 7-OH products, as the clinical presentations and severity profiles differ meaningfully and require different management approaches.

Bottom line

**The first clinical characterization of 7-OH toxicity from a U.S. poison center gives emergency clinicians a practical reference for managing 7-OH exposures—a critical distinction as high-potency products flood the market.**